Bivalirudin vs Epitalon
Overview
Bivalirudin is primarily a cardiovascular peptide, while Epitalon is used for anti-aging & longevity.
This page compares Bivalirudin and Epitalon across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Epitalon | |
|---|---|---|
| Category | Cardiovascular | Anti-aging & Longevity |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | 5-10 mg |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | cycle |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Areas studied (research-reported, not established efficacy): telomerase activation and telomere elongation in human cell lines (PMID 12937682; DOI 10.1007/s10522-025-10315-x); increased melatonin synthesis and circadian effects in a small human study; lower overall and cardiovascular mortality in a 12-15 year single-lab trial that used pineal extract (epithalamin), not synthetic AEDG (PMID 17426848, 22451889). No independent multi-center RCTs; not FDA-approved. |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Khavinson-group trials reported no serious adverse events (e.g., n=162 retinitis pigmentosa trial, PMID 12195242), but these are the only controlled safety data and remain unreplicated. Community use reports mild injection-site reactions. Theoretical concern: telomerase activation is a hallmark of most cancers, and a 2025 review (PMC11943447) notes carcinogenic potential is unstudied. No human pharmacokinetic or drug-interaction data. |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Epitalon falls under Anti-aging & Longevity. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Epitalon: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Epitalon is typically dosed at 5-10 mg (cycle).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Epitalon has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Epitalon?
- Bivalirudin is primarily a cardiovascular peptide, while Epitalon is used for anti-aging & longevity. Bivalirudin is FDA-approved for one or more indications, whereas Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Epitalon used for?
- Longevity, telomere support.
- Can you take Bivalirudin and Epitalon together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Epitalon has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Epitalon FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Epitalon — full monograph: mechanism, research, dosing & references